Table 2 Comparison of the sensitivity and specificity for ≥CIN3 of physician-collected specimens (endocervical), and vaginal self-collected assayed for HR-HPV by AmpFire, Cobas, SeqHPV (95% CIs and the actual patient numbers are in parentheses)
From: Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening
Specimen/High-Risk HPV Test | Sensitivity for ≥ CIN 3 (%) (CI) (n) | Specificity for ≥ CIN 3 (%) (CI)(n) |
|---|---|---|
Clinician Collected / AmpFire | 100% (88.29–100) (37/37) | 89.98% (89.18–90.72) (5403/6005) |
Self-Collected / AmpFire | 100% (88.29–100) (37/37) | 89.01% (88.18–89.78) (5345/6005) |
Clinician Collected / Cobas | 100% (88.29–100) (37/37) | 90.29% (89.51–91.02) (5393/6005) |
Self-Collected / Cobas | 97.30% (84.19–99.86) (36/37) | 87.70% (86.83–88.51) (5266/6005) |
Clinician Collected / SeqHPV | 100% (88.29–100) (37/37) | 90.54% (89.77–91.26) (5393/6005) |
Self-collected / SeqHPV | 100% (88.29–100) (37/37) | 89.94% (89.15–90.69) (5393/6005) |
Cytology | 100% (88.29–100) (37/37) | 95.97% (95.43–96.45%) (5763/6005) |